ArticleFrontiers in immunology2025
VSIG4 as a tumor-associated macrophage marker predicting adverse prognosis in diffuse large B-cell lymphoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- VSIG4 suppresses antitumor T cell immunity via the SLC3A2-dependent metabolic-ionic checkpoint.Journal for immunotherapy of cancer · 2026Article
- Identification and Validation of a Macrophage Phagocytosis-Related Gene Signature for Prognostic Prediction in Colorectal Cancer (CRC).Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diffuse large B-cell lymphoma (DLBCL) exhibits heterogeneous tumor microenvironment. However, the role of tumor-associated macrophages (TAMs) in the DLBCL tumor microenvironment remains unclear. This study aims to elucidate the heterogeneity of TAMs in DLBCL to identify critical TAM-associated prognostic biomarkers. Methods: Transcriptome data from DLBCL patients were obtained from online database. The CIBERSORT algorithm was applied to quantify TAM abundance across samples. Consensus clustering was used to stratify DLBCL into distinct clusters based on TAM subtype enrichment. Differential gene expression analysis, LASSO regression, univariate/multivariate Cox regression and Kaplan-Meier survival analysis were employed to identify key prognostic biomarkers. Validation of VSIG4+TAM subpopulation was performed using flow cytometry and multiplex immunohistochemistry. A local cohort of 375 DLBCL patients was investigated to explore the correlation between VSIG4 expression and various genetic and pathological characteristics including prognostic outcomes. Results: Four distinct DLBCL clusters, each enriched with specific TAM subtypes were found. The cluster dominated by M2 TAMs exhibited the worst prognosis. Differential analysis identified VSIG4 as a critical prognostic factor, with high expression in the M2 TAM-enriched cluster. Flow cytometry and mIHC confirmed VSIG4+ TAMs as a subpopulation within CD68+/CD163+ M2 macrophages. VSIG4 expression correlated with adverse genetic features (PIM1, ETV6, CD70 mutations) and aggressive pathological characteristics (non-GCB phenotype, MYC+/BCL-2 double-expression). Multivariate Cox regression confirmed VSIG4 as an independent prognostic factor for poor survival. Survival analysis suggested that VSIG4's prognostic impact operates independently of regulating lymphocyte infiltration, highlighting its unique role in DLBCL tumor microenvironment. Discussion: This study identifies VSIG4 as a TAM-associated marker of adverse prognosis of DLBCL and the expression of VSIG4 is related to high-risk genetic and pathological features. These findings position VSIG4 as a promising therapeutic target for immune checkpoint intervention in DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.